Turnstone Biologics Corp.
NASDAQ: TSBX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sammy J. Farah
- Employees
- 14
- Headquarters
- LA Jolla, United States
- IPO year
- 2023
- Market cap
- $8.2M
- Website
- https://turnstonebio.com
Loading TSBX…
Loading profile data…Frequently asked questions about TSBX
What does Turnstone Biologics Corp. (TSBX) do?
Turnstone Biologics Corp. is a clinical-stage biotechnology firm dedicated to developing therapeutic and curative treatments for patients battling solid tumor cancers. Its leading investigational drug, TIDAL-01, is currently undergoing Phase 1 clinical trials for indications such as breast cancer, colorectal cancer, and uveal melanoma. This comp...
Where does TSBX trade?
Turnstone Biologics Corp. (TSBX) trades on the NASDAQ Global Market.
What sector is TSBX in?
Turnstone Biologics Corp. (TSBX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Turnstone Biologics Corp.?
Sammy J. Farah is the chief executive officer of Turnstone Biologics Corp. (TSBX).
Where is Turnstone Biologics Corp. headquartered?
Turnstone Biologics Corp. is headquartered in United States.
Does TSBX pay a dividend?
Turnstone Biologics Corp. (TSBX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TSBX go public?
Turnstone Biologics Corp. (TSBX) completed its initial public offering in 2023.